Plunkett Research Online: Lixte Biotechnology Holdings Inc

LIXTE BIOTECHNOLOGY HOLDINGS INC (LIXT:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard ant.....



Lixte Biotechnology Holdings Inc
Ticker: LIXT
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 631 942 7959
Fax: 928 982 5050
Address: 680 East Colorado Boulevard
Suite 180
Pasadena, CA 91101 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceuticals
Contacts Description
Bastiaan van der BaanCEO/Chairman of the Board/Director/President
Robert WeingartenCFO/Vice President
See More
Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard ant.....See More See More

Auditor: WEINBERG & COMPANY, P.A.
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202320222021202020192018
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
NameTitleSalary (US$)Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: